Global Antibiotic R&D Partnership (GARDP)
Erika Mendes Correia is an experienced clinical trial manager with a robust background in clinical research, spanning from 1998 to the present. Currently serving as a Clinical Trial Manager at the Global Antibiotic R&D Partnership (GARDP) since August 2017, Erika has previously held positions such as Senior Clinical Research Associate at the Drugs for Neglected Diseases initiative (DNDi) from April 2012 to August 2017, and Associate Clinical Site Monitor at Bristol-Myers Squibb from August 2007 to August 2009. Erika's expertise encompasses protocol development, regulatory submissions, clinical monitoring, and adherence to ICH/GCP standards, alongside administrative roles in clinical trials. Erika's educational credentials include a Master of Business Administration (MBA) from FGV - Fundação Getulio Vargas and a Licentiate degree in Biology from UERJ.
Global Antibiotic R&D Partnership (GARDP)
The Global Antibiotic Research & Development Partnership (GARDP) is a not-for-profit organization that develops new antibiotic treatments for drug-resistant bacterial infections that pose the greatest threat to human health, and makes them accessible to the people who need them. It puts public health needs at the centre of antibiotic drug development to address both the immediate antimicrobial resistance (AMR) crisis and to ensure people continue to get access to essential antibiotics for generations to come. GARDP works through a global network including Brazil, India, Japan, and South Africa for antibiotic development and access. Its work is made possible by essential funding from donors and collaboration with over 100 R&D and access partners in over 20 countries. GARDP was created by the World Health Organization and the Drugs for Neglected Diseases initiative (DNDi) in 2016 and legally registered as the GARDP Foundation in Geneva, Switzerland in 2018. www.gardp.org